GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2006

PanGenetics Licenses Antibody from Schering-Plough

  • Schering-Plough granted PanGenetics exclusive rights to an undisclosed therapeutic antibody from its preclinical portfolio. PanGenetics will thus assume responsibility for the preclinical program as well as the initial clinical safety and efficacy evaluation.

    After a successful proof-of-concept clinical study, Schering-Plough has the option to either assume exclusive responsibility for further development of the antibody or enter into a co-development arrangement with PanGenetics.

    Genetics could earn in excess of $50 million in upfront and milestones payments. In addition, Schering-Plough has granted PanGenetics the option to license a second antibody from its portfolio. Also as part of the agreement, Schering-Plough will become a shareholder in PanGenetics.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?